{
    "2018-12-03": [
        [
            {
                "time": "2018-01-02",
                "original_text": "UPDATE 1-High-cost Gilead cell therapy proves durable for some lymphoma patients",
                "features": {
                    "keywords": [
                        "Gilead",
                        "cell therapy",
                        "durable",
                        "lymphoma"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-15",
                "original_text": "Novartis SMA treatment could get FDA approval in May",
                "features": {
                    "keywords": [
                        "Novartis",
                        "SMA",
                        "FDA",
                        "approval"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-10",
                "original_text": "Novartis: FDA Accepted BLA For SMA Type 1 Gene Replacement Therapy ZOLGENSMA",
                "features": {
                    "keywords": [
                        "Novartis",
                        "FDA",
                        "BLA",
                        "SMA",
                        "gene replacement",
                        "ZOLGENSMA"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}